Coronavirus News Roundup: Inhaler Shortages, Updates on Potential Treatments
March 27, 2020
Here’s a roundup of the latest coronavirus-related news from this week.
Recent Content
FDA Approves Ozanimod for Relapsing Multiple Sclerosis
March 27, 2020
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
Gilead to Rescind Orphan Drug Status for Remdesivir, a Potential COVID-19 Treatment
March 27, 2020
Gilead has now asked the FDA to rescind its orphan drug status for the potential COVID-19 therapy.
Study Examines Wide Range of Potential Influenza-Related Complications
March 26, 2020
Health care providers should look out for more than just respiratory diagnoses in patients when it comes to influenza-associated complications, according to a recent study.
AMA, APhA, ASHP Issue Joint Statement on Use of Medications to Treat COVID-19
March 26, 2020
In a joint statement, the American Medical Association (AMA), American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) have communicated concerns regarding the inappropriate ordering, prescribing, or dispensing of treatments for COVID-19.
New Treatment Approach Proposed for Respiratory Distress in COVID-19
March 26, 2020
Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.
CVS Caremark Sets Limits on Off-Label Treatments for COVID-19
March 25, 2020
CVS Caremark’s new quantity limits will not affect members who are already receiving these medications for their approved uses.
COVID-19: The Multifaceted Search for Potential Treatments
March 25, 2020
Convalescent plasma, hydroxychloroquine, and remdesivir among the potential COVID-19 treatment pathways being pursued.
Lopinavir-Ritonavir Shows No Substantial Benefit for Patients with COVID-19
March 25, 2020
A study investigated the use of lopinavir-ritonavir for the potential treatment of hospitalized patients with severe COVID-19.
Phase 3 Trial of Gefapixant Shows Favorable Efficacy Results for Chronic Cough Treatment
March 25, 2020
The trials demonstrated a significant decrease in 24-hour coughs per hour versus placebo at 12 and 24 weeks.
